Literature DB >> 8576893

Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents.

B J Materson1, D J Reda, W C Cushman, W G Henderson.   

Abstract

We randomised ambulatory men with diastolic blood pressure (BP) 95-109 mmHg without anti-hypertensive medication to single drug treatment with either hydrochlorothiazide 12.5-50 mg/day, atenolol 25-100 mg/day, captopril 25-100 mg/day, clonidine 0.2-0.6 mg/day, diltiazem-SR 120-360 mg/day, prazosin 4-20 mg/day or placebo in a double-blind prospective trial. The assigned drug was titrated to a goal BP of < 90 mm Hg. Patients not achieving goal BP were rerandomised to an alternative single active drug. Non-responders to the second drug received the first drug in combination with the second. Of the 102 non-responders to both drugs who qualified for the combination, 59 (57.8%) responded. The combination pairs that included a diuretic achieved diastolic goal BP in 69% and < 140 mm Hg systolic in 77% compared with 51% and 46%, respectively, for those combinations without a diuretic (P = 0.067; P = 0.002). Six of the eight terminations due to adverse drug reactions were in combinations containing prazosin; three of these six were hypotensive reactions. We conclude that two single drugs of insufficient efficacy to control BP individually have a high probability of achieving goal BP when combined, especially if the combination contains a diuretic.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576893

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  17 in total

1.  Contemporary management of refractory hypertension.

Authors:  A B Alper; D A Calhoun
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 2.  Natriuretic Peptides as a Novel Target in Resistant Hypertension.

Authors:  Pratik Patel; Horng H Chen
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

3.  Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement.

Authors:  Norman R C Campbell; Finlay A McAlister; Minh Duong-Hua; Karen Tu
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

Review 4.  Fixed low-dose combination therapy for hypertension.

Authors:  Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

Review 5.  Current drug treatment and treatment patterns with antihypertensive drugs.

Authors:  E D Freis; V Papademetriou
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 6.  Evolving strategies for the use of combination therapy in hypertension.

Authors:  Alan H Gradman; Celso Acevedo
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

Review 7.  Thiazide and loop diuretics.

Authors:  Domenic A Sica; Barry Carter; William Cushman; Lee Hamm
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-27       Impact factor: 3.738

8.  Hypertension treatment: contributions and comments on challenges.

Authors:  Edward Freis
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-01       Impact factor: 3.738

9.  Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Paula T Einhorn; Jackson T Wright; Richard A Preston; Barry R Davis; Jan N Basile; Paul K Whelton; Robert J Weiss; Arnaud Bastien; Donald L Courtney; Bruce P Hamilton; Kent Kirchner; Gail T Louis; Tamrat M Retta; Donald G Vidt
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-10       Impact factor: 3.738

10.  National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics.

Authors:  Elaine M Furmaga; Francesca E Cunningham; William C Cushman; Diane Dong; Rong Jiang; Jan Basile; Lois A Katz; Gale H Rutan; Dan R Berlowitz; Vasilios Papademetriou; Peter A Glassman
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.